Clinical Trials
17 trialsNCT02712723 2026-03-11
FELINE
University of Kansas Medical Center
Phase 2 Active not recruiting
NCT03673124 2025-12-23
Ribociclib and Letrozole Treatment in Ovarian Cancer
GOG Foundation
Phase 2 Active not recruiting
NCT03822468 2025-10-16
AMALEE
Novartis
Phase 2 Completed
NCT04256941 2024-12-27
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT02632045 2024-12-06
MAINTAIN
Columbia University
Phase 2 Completed
NCT03070301 2024-10-10
A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT03484923 2024-06-18
PLATforM
Novartis
Phase 2 Completed
NCT02159066 2024-03-05
LOGIC-2
Pfizer
Phase 2 Completed
NCT03477396 2024-02-20
Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT02657928 2021-10-26
Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer
Mayo Clinic
Phase 2 Completed
NCT03078751 2021-10-11
EarLEE-1
Novartis
Phase 2 Completed
NCT02524119 2021-02-01
LEE001
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT02420691 2020-10-30
Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02300987 2020-10-26
A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression
Novartis
Phase 2 Completed
NCT02187783 2019-07-18
SIGNATURE
Novartis
Phase 2 Completed
NCT01919229 2016-01-01
MONALEESA-1
Novartis
Phase 2 Terminated